Breakthrough Vaccine for Over 60s: mRNA Technology Tackles Respiratory Syncytial Virus
2025-02-28
Daily Mail
In a significant development, a new vaccine has been approved for individuals over 60, utilising mRNA technology, similar to the Covid-19 vaccine. The vaccine, developed by Moderna, has been shown to substantially reduce the risk of severe illness from respiratory syncytial virus (RSV), offering hope for improved health outcomes in this age group. With its innovative mRNA approach, this vaccine has the potential to provide enhanced protection against RSV, a common and potentially serious respiratory illness. As the vaccine becomes available, it is expected to have a positive impact on public health, particularly among older adults. Key terms: mRNA technology, RSV vaccine, respiratory health
